Loading...
Loading...
From peptide formulation to commercial CQV — a guided end-to-end journey for GLP-1 manufacturing with embedded tool links at every stage. Six tools open as public previews without sign-in; request invite access for the full evaluation sandbox.
For a modality-agnostic map with the same access badges, see the Digital CMC Lifecycle Playbook.
Track formulation → DSP → PM/CQV artifacts on a 24-month program timeline (month 18 · 6 months to GMP readiness).
Scaling GLP-1 analogues from pilot to commercial scale is a thermodynamic, hydrodynamic, and regulatory coordination challenge. This playbook lists every relevant suite at each phase so prospects see the full platform scope.
Tools marked Public Preview open immediately. Items marked Access Required link to the tool but redirect to sign-in or an invite unless you have platform access.
Before designing a downstream process, understand the biophysical properties that will govern every purification decision. For GLP-1A/GLP-1B-class peptides, the isoelectric point (pI ≈ 5.4–5.5) is the single most critical parameter — it determines aggregation risk under shear, optimal buffer conditions, and membrane compatibility.
Key Questions at This Stage
TFF is the workhorse of peptide downstream processing — used for buffer exchange, concentration, and diafiltration. The interaction between wall shear rate, buffer pH, and membrane material determines whether you achieve 97% yield or trigger irreversible aggregation. Design these parameters together, not in isolation.
Key Questions at This Stage
Before committing to commercial hardware, every critical process parameter and equipment attribute needs a formal risk assessment. An FMEA at this stage costs days; discovering the same failure mode during CQV costs months. ICH Q9 provides the framework — Severity × Occurrence × Detection = RPN — and any item above the acceptance threshold (typically 150) requires a mitigation plan before proceeding.
Key Questions at This Stage
Scaling from a 10 L pilot to a 24,000 L commercial facility exposes every design assumption. Two-inch piping creates dead legs that trap 0.65 L per meter. Twenty TFF cassettes retain 9 L of product void volume. The Minimum Working Volume (MWV) — the pump-cavitation floor — is 1.5× that hold-up. At commercial scale this can represent 15–20% of your batch, directly limiting concentration factor and yield. Plan this before construction.
Key Questions at This Stage
Platform Tools
CDMO Dashboard
Checking access…Vendor batch tracking and program KPIs
PM & Scope Control Suite
Checking access…Scope Creep Cascade and Change Impact Assessor
Tech Transfer Package
Checking access…CPP/CQA, equipment fit, analytical transfer, and documentation index
CAPEX / OPEX Calculator
Checking access…Equipment and operational cost modeling
Commissioning, Qualification, and Validation is the final compliance gate before commercial manufacture. Every TFF skid, UF/DF system, and buffer prep suite requires IQ, OQ, and PQ documentation. At a $300M facility this represents hundreds of individual deliverables across multiple vendors and contractors. A single missing protocol signature holds up the entire facility startup. The Change Control Log is your lifeline for managing late-stage engineering requests without derailing the critical path.
Key Questions at This Stage
Platform Tools
Commercial launch is not the end of the engineering journey — it is the beginning of the MSAT lifecycle. Process monitoring, supply chain management, CDMO oversight, and continuous improvement all require the same cross-functional data visibility that drove the build. Maintaining a 'single source of truth' across regulatory submissions, batch records, and deviation investigations is the difference between a steady-state process and an audit finding.
Key Questions at This Stage
Platform Tools